IP Library Granted Patent US 8,133,875
Granted Patent B2
US 8,133,875 · App. 12/104,105 · Granted Mar 13, 2012

Method for inhibiting scavenger receptor-A and increasing immune response to antigens

Assignee: Health Research Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,133,875
App. No.
12/104,105
Granted
Mar 13, 2012
Kind
B2
Abstract

Provided is a method for enhancing an immune response to a desired antigen in an individual. The method is performed by administering to the individual an agent capable of inhibiting class A macrophage scavenger receptor (SR-A) and optionally administering the desired antigen. Also provided is a method for enhancing an immune response to an antigen by administering to an individual a composition containing antigen presenting cells that are characterized by specifically inhibited SR-A. Substantially purified populations of mammalian dendritic cells characterized by specifically inhibited SR-A are also provided.

Claims (4)

1. A method for enhancing in an individual an immune response to a desired antigen comprising administering to the individual an effective amount of a composition comprising dendritic cells, wherein the dendritic cells are characterized by having specifically inhibited class A macrophage scavenger receptor (SR-A), wherein the SR-A activity of the dendritic cells is specifically inhibited by an shRNA that is targeted to SR-A mRNA, and wherein the administering the composition enhances the immune response to the desired antigen in the individual.

2. The method of claim 1 , wherein the dendritic cells have been exposed to the desired antigen prior to administration to the individual.

3. The method of claim 1 , wherein the individual has been diagnosed with a tumor which expresses the desired antigen, and wherein the growth of the tumor is inhibited subsequent to administering the composition comprising the dendritic cells.

4. The method of claim 1 , wherein the dendritic cells are isolated from the individual and are exposed to the desired antigen after isolation but prior to administering the composition to the individual.

Assignments (3)
CONFIRMATORY LICENSE Recorded Mar 15, 2010
From: HEALTH RESEARCH, INC. ROSWELL PARK CANCER INSTITUTE DIVISION
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 024076/0983 →
CONFIRMATORY LICENSE Recorded Mar 15, 2010
From: ROSWELL PARK CANCER INSTITUTE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 024077/0388 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 28, 2008
From: WANG, XIANG-YANG; SUBJECK, JOHN
To: HEALTH RESEARCH, INC.
Reel/Frame 021007/0558 →
Continuity (2)
Provisional Application 60923628 · Apr 16, 2007
Related Publication 20080254072A1 · Oct 16, 2008